医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Listing on the Tokyo Stock Exchange Prime Market

2024年10月25日 PM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; “Rigaku”), has completed its listing on the Tokyo Stock Exchange Prime Market as of today.

Note: This document is a press release intended for public announcement regarding Rigaku’s listing on the Tokyo Stock Exchange Prime Market. It has not been prepared for the purpose of soliciting investments or any similar acts, whether within or outside Japan.

This press release does not constitute an offer or sale of securities in the United States. The shares of common stock of Rigaku may not be offered or sold in the United States absent registration or an exemption from requirement. If any public offering of the shares of common stock of Rigaku is made in the United States, it will be by means of a prospectus that may be obtained from Rigaku or the selling shareholders and that will contain detailed information about Rigaku and its management, as well as financial statements. No public offering of the shares of common stock of Rigaku will take place in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241025783775/en/

CONTACT

Press Contact:

Sawa Himeno

Head of Communications Dept., Rigaku Holdings Corporation

+81 90 6331 9843

prad@rigaku.co.jp

同じカテゴリーの記事 

  • Rigaku Holdings Corporation在东京证券交易所主要市场上市
  • Listing on the Tokyo Stock Exchange Prime Market
  • LabGenomics USA Completes Acquisition of IMD CLIA Labs
  • Dr. Reddy’s Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
  • Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).